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Abstract 
Polymeric micelles, in particular PEO-PPO-based Pluronic, have emerged as 
promising drug carriers, while cyclodextrins, cyclic oligosaccharides with an apolar 
cavity, have long been used for their capacity to form inclusion complexes with drugs. 
Dimethylated β-cyclodextrin (CD) has the capacity to fully break-up F127 Pluronic 
micelles, while this effect is substantially hindered if drugs are loaded within the 
micellar aggregates. Four drugs were studied at physiological temperature: lidocaine 
(LD), pentobarbital sodium salt (PB), sodium naproxen (NP), and sodium salicylate 
(SAL); higher temperatures shift the equilibrium towards higher drug partitioning and 
lower drug:CD binding compared to 25°C.1 The impact of drugs on micellar structure 
was characterised by small-angle neutron scattering (SANS), while their solubilisation 
locus was revealed by 2D NOESY NMR. UV and fluorescence spectroscopy, Dynamic 
and Static Light Scattering were employed to measure a range of micellar properties and 
drug:CD interactions: binding constant, drug partitioning within the micelles, critical 
micellar concentration of the loaded micelles, aggregation number (Nagg). Critically, 
time-resolved SANS (TR-SANS) reveal that micellar break-up in the presence of drugs 
is substantially slower (100s of seconds) than for the free micelles (< 100 ms).2 These 
results combined together give new insights into the mechanisms of protection of the 
drugs against CD-induced micellar break-up. The outcomes are practical guidelines to 
improve the design of drug delivery systems as well as an improved understanding of 
competitive assembly mechanisms leading to shape and function modulation. 
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Introduction  
Pluronic micelles, comprising a central poly(propylene oxide) (PPO) block flanked by 
two poly(ethylene oxide) (PEO) blocks, are emerging promising drug carrier candidates, 
particularly in the cancer arena.3-5 They meet a number of key requirements as effective 
therapeutic agents: a distinct core-shell architecture providing physical entrapment of 
hydrophobic drugs, while reducing recognition by macrophages with their hydrophilic 
PEO corona; preferential accumulation within tumours and enhanced permeability and 
retention (EPR effect); inhibition of drug efflux pumps involved in multi-drug 
resistance.5 Pluronic-based micellar formulation of the anticancer drug Dox, SP1049C, 
was the first polymeric micelle drug to advance to clinical stage, successfully 
completing phase II clinical trial in advanced oesophageal cancer patients.5, 6 
While the positive features of Pluronics as drug carriers have long been recognised, and 
current clinical trials are demonstrating efficiency and safety, their potential still needs 
to be fully realised. A key issue in the realisation of this potential is the lack of 
understanding of structure-property relationships, in particular: how a specific drug 
structure relates to its solubilisation within a specific micellar architecture, and 
ultimately its release from the carrier. We have previously investigated the structure of 
Pluronic F127 micelles when loaded with drugs of different structure, showing 
substantial changes to micellar size depending on the nature of the loaded drug,1, 7 in 
agreement with other reports;8, 9 however, the rules that govern the loading ability of the 
micelle or the effect of the drug on the structure of the micelle are a long way from 
being established. For instance, it has been suggested that the partitioning of aromatic 
compounds into Pluronic micelles is strongly favoured,10 while the presence of charge 
strongly limits their partitioning.1 
In addition to drug-micelles interactions, our interest over the last few years has focused 
on ternary systems where cyclodextrins (CD) are present, which can both bind the drugs 
(forming an inclusion complex) and interact with the polymer, leading to interesting 
competitive interactions. CDs are cyclic oligosaccharides of conic shape, with a 
hydrophilic exterior and a relatively hydrophobic internal cavity, widely used in the 
pharmaceutical industry to solubilise lipophilic drugs.11 Their interaction with polymers 
or amphiphiles can lead to a range of supramolecular structures that have been widely 
reviewed in the literature.12, 13 Dimethylated β-cyclodextrin (DIMEB) - which has two 
hydrogens substituted by a methyl group on each glucose unit - interacts with Pluronic 
micelles by hindering micellisation, breaking them up completely at high 
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DIMEB/Pluronic ratio.1, 2, 7 This destructive interaction is surprisingly selective and is 
not observed (or much reduced) with other CD derivatives.7 The demicellisation 
induced by DIMEB – probably linked to an optimum balance between hydrophobicity 
and hydrogen-bonding ability - seems to be quite a generic feature of this cyclodextrin, 
as recently shown for X-shaped PEO-PPO block copolymers (poloxamines or 
Tetronics).14, 15 This selective interaction is thus envisaged for the controlled release of 
drugs in specific body compartments.1 Interestingly, the extent of this effect is not only 
controlled by composition (DIMEB/F127) ratio but also strongly dependent on the 
nature of the loaded drug: some drugs hinder DIMEB disruptive effect (thus 
‘protecting’ the micelles), but to varying extents; the mechanisms, however, are not 
understood.2, 16 
The current study focuses on physiological temperature (37°C). Not only is this 
temperature more relevant to drug studies, but by increasing the temperature several 
changes occur: micellisation is enhanced, drug partitioning increases,17, 18 while 
drug:CD binding generally decreases. These changes in the balance of interactions give 
us a useful handle to gain new insights into the mechanisms, by contrasting and 
comparing to the situation at room temperature.1 An important aspect of drug delivery 
systems (DDS) is the localization of the drugs within the aggregates; the locus of 
solubilisation is expected to correlate with important features such as drug loading and 
release rate from the aggregates.19 Despite being such a key property, the drug 
solubilisation locus is usually unknown and scarcely studied. We report here 2D NMR 
data that provide information on drug localization, and which are then correlated with 
micellar structural features and drug partitioning. 
This work focuses on the four drugs previously studied (Scheme 1): lidocaine 
(LD), pentobarbital (PB), salicylate (SAL) and naproxen (NP); the first is uncharged 
while the latter three are in their sodium salts, thus charged (at natural pH), and present 
different sizes of the polar and apolar regions. We use spectroscopic techniques (UV, 
fluorescence, NMR) in combination with static (SLS) and dynamic light scattering 
(DLS), small-angle neutron scattering (SANS) and time-resolved-SANS (TR-SANS), to 
examine the following aspects: the effect of drug loading on micellar structure and 
micellar properties; the partitioning of the drugs inside the micelles and their 
localization; the binding of the drugs to DIMEB, the critical micellar concentration, and 
the kinetics of micellar rupture. These results are then combined to discuss the 
mechanisms of protection of the drugs against DIMEB-induced micellar break-up. 
5 
 
 
 
Experimental section 
Materials 
Pluronic copolymer F127 comprising a central block of 65 PPO units and two side-
blocks of PEO (100 units each) was obtained from Sigma-Aldrich UK (Mw = 12,600). 
Heptakis(2,6-di-O-methyl)-β-cyclodextrin (DIMEB) was obtained from Sigma-Aldrich 
UK (H0513, Mw = 1331.4 g mol-1). 
The drugs naproxen sodium salt (NP, M1275), pentobarbital sodium salt (PB, P3761), 
sodium salicylate (SAL, 71945) and lidocaine (LD, L7757) were purchased from Sigma 
Aldrich (Scheme 1). Methyl Orange (MO) was purchased from Panreac. All materials 
were used as received. 
 
Sample Preparation  
Aqueous stock solutions of (1) drug alone, (2) drug/F127, and (3) drug/DIMEB, as well 
as combined (4) drug/F127/DIMEB were prepared by weight. For partition coefficient 
determination, solutions of different F127 concentrations were prepared by mixing the 
appropriate amount of solutions (1) and (2). For the determination of drug:CD binding 
constants in the absence and the presence of F127, solutions (3) and (1) were mixed 
with (4) and (2), respectively. In the case of lidocaine (the only one not in salt-form), 
the solutions were heated above the drug melting point (68°C) to facilitate diffusion and 
solubilisation into the micellar core. The solutions were then cooled back to room 
temperature.  
For the determination of the critical micellar concentration (cmc), solutions (1) and (2) 
were prepared in MO/H2O (4×10-5M), with and without drug for loaded and free 
micelles respectively. A range of F127 concentrations were obtained by mixing varying 
amounts of both solutions.  
All solutions were prepared by weight and ‘%’ always refers to weight %. 
 
SANS measurements 
Static SANS measurements were carried out on LOQ at the ISIS facility (Rutherford 
Appleton Laboratory, Didcot, UK). LOQ uses incident wavelengths from 2.2 to 10.0 Å, 
sorted by time-of-flight, and a fixed sample-detector distance of 4.1 m. This provides 
access to scattering vectors q from 0.009 to 0.287 Å-1. The scattering intensity was 
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converted to the differential scattering cross-section in absolute units using the standard 
procedures at each facility. 
Time-resolved SANS (TR-SANS) were performed on the D22 instrument at the Institut 
Laue Langevin (ILL, Grenoble, France). The wavelength  was set at 6 Å, the peak flux 
of the cold source. The sample-to-detector distance was 4 m with a collimation at 5.6 m 
and a detector offset of 400 mm to maximize the available q-range (1.2 × 10-2 Å-1 < q < 
0.26 Å-1). A 7 × 10 mm2 sample aperture was used, and the sample path length in the 
Biologic SFM-300 stopped-flow apparatus was 1 mm. Further experimental detail can 
be found in our previous publication.2 
 
Modelling of SANS data 
Scattering curves from the Pluronic micelles with and without drug were fitted to a 
core-shell sphere (CSS) model combined with a hard-sphere structure factor using the 
SasView 3.0.0 software.20 A Gaussian coil with Rg = 7 Å was added to improve the 
modelling in the high-q region, which originates from the PEO shell. From a 
combination of micellar size and solvent penetration (obtained from the fitted value of 
the scattering length density (sld) of the shell), it is possible to estimate an aggregation 
number, Nagg, as described in a previous publication.14 
The scattering from Pluronic micelles with drug and varying amounts of DIMEB were 
fitted using a combined model comprising a core-shell sphere (CSS) interacting through 
a hard-sphere structure factor (for the micelles) and simple spheres (radius 10 Å) to 
model the cyclodextrins (no Gaussian coil was added in this case, in order to keep the 
number of parameters reasonably low). Polydispersity (with a Gaussian distribution of 
sizes) was applied to both the core and the shell. 
 
Fluorescence measurements 
Measurements were performed on a Cary Eclipse fluorescence spectrophotometer 
(Varian, Oxford, UK). 
Two regimes of drug concentration were used: dilute (10-3 wt%) and concentrated (2 
wt%) for NP, PB and SAL and 0.3 % for LD, as determined by its aqueous solubility.21 
The aqueous solutions were prepared using ultra-pure water (18.2 MΩ.cm). 
The following excitation wavelengths were used for the drugs: Lidocaine: λexc= 262 nm; 
pentobarbital: λexc= 240 nm; naproxen sodium salt: λexc= 317 nm; sodium salicylate: 
λexc= 296 nm. 
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The binding constant of the drugs to F127 micelles were determined using the method 
proposed by Almgren.22 
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where CM is the micellized surfactant concentration with CM = (CS – cmc), CS being the 
total surfactant concentration, F is the measured fluorescence intensity, F0 and F are 
the fluorescence intensity when all the drug is free and complexed, respectively. KF127 is 
the binding constant of the drug to the micelle, obtained by fitting the experimental 
data.  
F0 is an experimental parameter, while F cannot always be obtained experimentally 
thus Eq. (1) is rearranged to obtain: 
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Plots of F0/(F-F0) vs 1/CM give a linear plot, where the ratio of the y-intercept over the 
slope gives KF127. 
The binding constants of the drugs to F127 micelles were calculated using the cmc 
values presented in Table 1 (obtained from UV-vis absorbance spectroscopy with 
methyl orange). The binding constant of each drug (in dilute conditions, at 10-3%) to 
cyclodextrin, KDIMEB, was determined using the following expression: 
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   Eq. (3) 
where F is the measured fluorescence intensity, F0  and F are the fluorescence intensity 
when all the drug is free and complexed, respectively; F0 is the experimental value in all 
cases F is the experimental value for NP and SAL, whereas in the case of LD and PB, 
F value was obtained by fitting. [CD] is the concentration of free cyclodextrin, which, 
in these dilute systems, corresponds to the analytical concentration, since [CD] >> 
[drug]. A non-linear least squares method was used to fit the experimental results to Eq 
(3) and obtain KDIMEB. The [CD] concentration used was expressed in mass fraction (X) 
for consistency of units between all experiments; as a result, the binding constant, which 
is expressed in inverse of concentration units, X-1: g/g. 
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Cmc determination by UV-Vis absorbance 
The cmc of F127 micelles in the absence and presence of each drug was measured using 
methyl orange as a probe for UV-vis absorbance spectroscopy. Methyl orange is a dye 
with a strong absorbance in the visible region of the spectrum, sensitive to the nature of 
the microenvironment in which it is present. This probe was selected because it absorbs 
far from the drugs. A blue shift (lower wavelength) in the MO absorption maximum is 
observed when the probe is transferred from water to a less polar media.23 Owing to this 
sensitivity, MO has been widely used for cmc determination.24 
The absorption spectra of MO in the presence of increasing amounts of F127 were 
measured on a Jenway (Model 7315) uv-vis spectrophotometer in cells of 1 cm optical 
path length. The concentration of MO (410-5 M) was kept constant. The position of the 
maximum is blue-shifted with increasing F127 concentration (SI 1) showing the transfer 
of MO from bulk water to the less polar micellar microenvironment, therefore signalling 
the onset of micellisation. 
In general, the attribution of a single cmc value to this type of non-ionic surfactants is 
problematic;17 indeed, a wide range of cmc values have been published for Pluronics, a 
fact generally attributed to batch-to-batch variation and the inherent polydispersity of 
the polymers, added to a dependence on the technique used. Extrapolation of straight 
lines can lead to important errors in the estimation of the cmc and we have opted for the 
fit of the absorbance maximum with a logistic curve, as this model accounts for 
aggregation processes, either cooperative or not.25 In a “classical” surfactant, in which 
the transition is sharp, the cmc is associated with the inflection point. However, if 
aggregation occurs over a broad range of concentrations (as is the case), a criterion that 
better measures the onset of aggregation is preferred. We have considered here the cmc 
as the concentration at which 1% of the change in the trend of the fit occurs (which can 
be deduced easily from the logistic curve, SI 2). 
 
NMR Measurements.  
Solutions of 5% F127 with 1 % drug salts or 0.65 % lidocaine in F127 and 0.3% in 
D2O. The 1H 1D and 2D NMR spectra were recorded on a Bruker Avance 500 
spectrometer operating at 500 MHz proton frequency. The (1H-1H) NOESY 
experiments were acquired with mixing time of 100, 300 and 500 ms; 512 experiments 
were performed in the F1 dimension with 16 scans for each of the t1 increments and 
sweep width of 6.6 ppm. Selective 1H-NOESY experiments were carried out by using 
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soft Gaussian pulses and library pulse sequence. Self-diffusion coefficients were 
measured by PFG experiments. A pulsed gradient unit capable of producing magnetic 
field pulse gradients in the z-direction of 53 G cm-1 was used. All the experiments were 
performed using the bipolar pulse longitudinal eddy current delay (BPPLED) pulse 
sequence. The duration of the magnetic field pulse gradients () and the diffusion times 
() were optimized for each sample in order to obtain complete dephasing of the signals 
with the maximum gradient strength. In each DOSY experiment, a series of 64 spectra 
with 32K points were collected. For the investigated samples,  values were in the range 
2-3 ms, while the  values were in the range 0.1-0.5 s. The pulse gradients were 
incremented from 2 to 95% of the maximum gradient strength in a linear ramp. The 
temperature was set and controlled at 310K with an air flow of 535 l h-1 in order to 
avoid any temperature fluctuations due to sample heating during the magnetic field 
pulse gradients. 
Hydrodynamic radii of free and loaded F127 micelles in D2O, were calculated from the 
diffusion coefficients, D0, using the Stokes- Einstein equation (Eq. 4), assuming that the 
aggregates are spherical and non-interacting. 
 
𝑅ℎ =
𝑘𝐵𝑇
6𝜋𝜂𝐷0
         Eq. (4) 
 
where kB is the Boltzman constant, T the absolute temperature and  the solvent 
viscosity. D2O viscosity was taken as 1.110-3 Pa·s at 25º and extrapolated to 0.83610-
3 Pa·s at 37ºC from reference.26 
 
Light scattering measurements 
Both size distributions and molecular weight determination of the micelles were 
obtained with a Malvern Zetasizer Nano light scattering apparatus with a laser 
wavelength of 633 nm. The samples were prepared in D2O (to match the conditions 
used for SANS) and filtered prior to the measurements by 0.22 m Millex syringe 
PVDF filters onto semi-micro glass cells, and the temperature fixed at 37.0 ºC  0.1ºC 
with the built-in Peltier in the cell compartment. The viscosities and refractive indices 
of D2O at 37ºC were taken into account to obtain the particle size distribution from the 
analysis of the autocorrelation function, which was performed with the Zetasizer 
software. This built-in software uses cumulant and non-negative least squares 
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algorithms to calculate the size distribution; both methods have been used to analyse the 
DLS data and give consistent results. A dn/dc = 0.133 mL g-1 was used for the 
molecular weight determination of the micelles. Considering the large range of 
surfactant concentration in the Debye plots (up to 5%), very good fits were achieved 
with a 2nd order polynomial (third virial coefficient in the c2 term). 
Micellar aggregation numbers, Nagg (shown in Table 2) were calculated from the 
number of drug molecules inside the aggregates (SI 3), molecular weight of loaded and 
free F127 micelles (5%) at 37ºC by using Eq. 5: 
 
𝑀𝑊𝑙𝑜𝑎𝑑𝑒𝑑 𝑚𝑖𝑐𝑒𝑙𝑙𝑒 = 𝑁𝑎𝑔𝑔𝑀𝑊𝐹127 𝑚𝑜𝑛𝑜𝑚𝑒𝑟 + 𝑁𝑑𝑟𝑢𝑔𝑀𝑊𝑑𝑟𝑢𝑔  Eq. (5) 
 
Results and Discussion  
 
Micellar structure: effect of the drugs, effect of cyclodextrin 
Effect of loading drugs in the micelles 
For the free and drug-loaded micelles at 37ºC, the scattering length density (sld) of the 
core was fixed at 0.410-6 Å-2 (sld of PPO, corresponding to no solvent penetration). 
The sld of the shell was fitted and found to be ca. 5.9510-6 Å-2, reflecting a high level 
of hydration (92-95%) (Table 3). Neutrons are then mainly sensitive to the micellar 
core and the thickness of the hydrophilic shell cannot be determined in a very accurate 
way, within ± 5 Å. For all micelles, the hard sphere volume fraction 25±1% and 
polydispersity was applied to the radius (0.15) and the shell (0.2). This model gives for 
5% F127 micelles a core radius of 45 Å, shell thickness of 64 Å and Nagg of 40 (in good 
agreement with the value of 39 obtained for 3% F127 at 35°C using a different 
model).27 
The scattering signal from micelles loaded with 0.5, 1 and 2% PB shows little variation 
from the free micelles (Figure 1A), with only a very slight decrease in intensity, 
reflecting a slight decrease in micellar size. In contrast, at 25ºC, a slight increase in 
intensity had been observed (together with marginally stronger inter-micellar repulsion), 
which suggested a slight swelling of the micelles by the drug,1 thus pointing to a shift in 
the balance of forces with temperature and compatible also with a small contribution of 
unspecific aggregates - typical of this type of block copolymers - which may still be 
present at this temperature. This slight decrease in size at 37°C is confirmed by 
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measurements of the hydrodynamic radius by DLS and the core radius in SANS (Table 
3). The hydrodynamic radius of PB-loaded micelles obtained by diffusion NMR (16.6 
and 7.5 nm) are higher and lower than the corresponding free micelles (9.0 nm and 8.8 
nm) at 25 and 37ºC, respectively, thus confirming the opposite effects (although minor) 
obtained at r.t. and physiological temperature. 
In contrast, the presence of both naproxen and salicylate sodium salts produces a visible 
decrease in micellar size, as observed at 25ºC,1 which is more pronounced as the 
amount of drug increases, and is attributed to increased electrostatic repulsions inside 
the micelles, due to the partitioning of the charged drugs (Figure 1B, Table 3). At 
equivalent concentration, the addition of NP reduces the size of the micelles to a larger 
extent than SAL. 
Finally, the addition of lidocaine induces a net increase in the scattered intensity and a 
net shift of the second oscillation (around ca. 0.1 Å-1) to lower q values, reflecting a 
swelling of the micellar core (Figure 1C, Table 3). This unambiguously shows that the 
hydrophobic, uncharged drug becomes solubilized in the micellar core, as also observed 
at 25ºC.1 The sld of LD was not taken into account in the fits (equally for the other 
drugs) and sldcore was kept at 0.410-6 Å-2. A two-shell model (with a core of LD) was 
attempted but did not improve the fits. This swelling of the micelles by lidocaine had 
previously been reported for concentrated solutions of F127 (18 %) with 1 and 2 % 
lidocaine, using a paracrystalline model to fit the data,7 with an increase of mean radius 
from 43 Å with no lidocaine to 48 Å and 53 Å with 1 and 2% lidocaine, respectively. 
Overall, the effect of the drugs on micellar size is similar to those previously observed 
at 25°C:1 LD swells the micellar core, PB produces very minor changes, NP and SAL 
both shrink the micelles. This provides us with four different structures and scenarios to 
elucidate the competitive interactions in ternary systems formed by the same drugs with 
micelles and cyclodextrins. 
 
Disruptive effect of cyclodextrin; protective effect of drugs 
The addition of increasing amounts of dimethylated β-cyclodextrin (DIMEB) at 37°C 
produces a progressive rupture of the micelles, both for the free micelles and the drug-
loaded micelles (Figure 2), as had been observed with this specific cyclodextrin at 
25°C,1 other Pluronics (P85 and P123)2 and other PEO-PPO-based block-copolymers.14, 
15 Interestingly, the rupture of the drug-loaded micelles is hindered compared to the free 
micelles, i.e. higher amounts of DIMEB are required to produce a comparable reduction 
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in size, which is easily seen by observing overlapping scattering curves in Figure 2, or 
comparing micellar size obtained from fitting the curves to a core-shell model with a 
contribution from the cyclodextrins as spheres (Table 4), as described in the 
Experimental section. For instance, 11% of DIMEB need to be added to PB-loaded 
micelles to produce about the same effect as only 7% DIMEB on free micelles (Figure 
2A, Table 4). Similarly, 13% DIMEB added to either PB- or NP-loaded micelles 
produces micelles with a comparable core-size than only 9% DIMEB added to free 
micelles (Figure 2A, Table 4). SAL-loaded micelles with 9% DIMEB are much larger 
than free micelles with the same amount of DIMEB (Figure 2B, Table 4), despite SAL-
loaded micelles being smaller to start with (equally NP-loaded micelles). With LD, a 
protective effect had also been reported previously.7 Figure 2C shows for instance that 
7% DIMEB added to free F127 produces a scattering similar to 11% DIMEB added to 
LD-loaded micelles, or that 9% DIMEB added to free micelles yield a size similar to 
LD-loaded micelles with as much as 13% DIMEB added (Table 4). With LD however 
the comparison is less straightforward as LD-loaded micelles (in the absence of 
DIMEB) are larger than free F127 micelles.  
 
Generally, drug-loaded micelles are more resistant to disruption against DIMEB than 
free F127 micelles, but how do each drug compare to the others?  
If we compare the effect of NP and SAL, we observe that for the same amount of 
DIMEB (9 and 13%), micelles loaded with NP are larger than SAL-loaded micelles 
(Figure 2B, Table 4), despite NP-loaded micelles being slightly smaller to start with 
(Figures 1B, Table 3). In other words, NP is more efficient in protecting the micelles 
than SAL, despite the similarities in their chemical structure. Comparing LD and PB 
(Figure 2C), it appears that PB-and LD-loaded micelles with 11% added DIMEB show 
a very similar scattering (PB-loaded micelles marginally larger, Table 4); from these 
equivalent structures, an additional 2% DIMEB (up to 13% DIMEB) induces a larger 
extent of disruption in PB-loaded micelles (lower curve, Figure 2C) than in LD-loaded 
micelles, thus suggesting a higher protective effect of LD vs. PB (although the effect is 
quite moderate). Comparing PB and NP, it appears that for the same amount of added 
DIMEB (9 and 13%) the curves of PB- or NP-loaded micelles exactly overlap (Figure 
2A), reflecting similar micelle sizes (Table 4); since PB-loaded micelles are larger to 
start with (Table 3), this suggests that NP has a higher protective effect. We note that 
NP, PB and SAL-loaded micelles have generally larger shell thicknesses, which may be 
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due to the superficial localization of these drugs (a point clarified later using 2D NMR), 
leading to higher hydration. 
 
Overall, it appears that while all drugs protect the micelles against disruption by 
DIMEB, they do this to various extents. Over the range of compositions studied, we 
find that the protective effect is: NP>SAL, NP>PB and LD>PB. How do drugs ‘protect’ 
micelles against rupture by DIMEB? In these systems with three components, where 
each can interact with the two others, hindrance to micellar rupture may be attributed to 
either:1 (1) a stabilization of the micelles by the drugs, controlled by drug-polymer 
interactions; (2) the formation of drug:cyclodextrin inclusion complexes, leading to a 
lower effective amount of cyclodextrin molecules available to rupture the micelles. 
Previous studies at 25°C1 suggested that both mechanisms needed to be accounted for in 
the case of PB, while for NP and SAL competition alone (mechanism (2)) could be 
sufficient to explain the protective effect (the conditions at 25°C, however, did not 
allow us to exclude mechanism (1)). In order to elucidate the interactions present in 
these ternary systems, we next quantify the affinity of the molecules with each other, by 
measuring drug:CD binding constants (responsible for mechanism (2)) and the 
partitioning of the drugs within the micelles (responsible for mechanism (1)). 
 
Quantifying the drugs affinity to cyclodextrin and polymer 
Drug:CD binding constants  
The binding constant of all four drugs to DIMEB was determined by fluorescence 
spectroscopy, using the natural fluorescence of the drugs. The addition of DIMEB to the 
drug solutions produces a hyperchromic effect, reflecting an interaction between the 
drugs and DIMEB. For all four drugs, a good fit of the plot of emission maxima vs. CD 
concentration is obtained by assuming a 1:1 stoichiometry (Eq. 3, Figure 3A). The 
values of the binding constants (Table 5) are lower than the ones determined at 25ºC for 
all four drugs,1 in agreement with an inclusion complex formation being an exothermic 
process.28-30 Therefore, at 37ºC, the competitive mechanism (2) - attributed to the drugs 
complexing with cyclodextrin - is weaker compared to the situation at 25ºC. 
The same measurements were carried out in the presence of Pluronic micelles (5%). In 
all cases, similar changes in the spectra were observed with the addition of cyclodextrin, 
clearly showing that drug:DIMEB complex formation still takes place in the presence of 
the polymer (Figure 3B). Therefore, in spite of drug partitioning within the micelles 
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and a lower drug:DIMEB binding (compared to 25ºC), F127 and drug still compete for 
interacting with the cyclodextrins.  
In order to quantitatively test mechanism (2), we consider an extreme scenario with no 
drug partitioning inside the micelles (i.e. all the drug interacts preferentially with 
DIMEB); this corresponds to the most competitive scenario between drug and polymer. 
Using the binding constants determined in Table 5, we have calculated the amount of 
free cyclodextrin, [CD]free, (SI 4), i.e. the amount of effective cyclodextrin available to 
interact with the polymer for a total cyclodextrin concentrations, [CD]tot, of 13% for 1% 
NP and PB and 9% for 1% SAL loaded micelles; in these conditions the loaded micelles 
present the same size than free micelles in the presence of [CD]tot of 9 and 7% of 
DIMEB, respectively, as shown by SANS data (Table 4). The [CD]free calculated (i.e. 
not complexed with the drug) would be 12.3% and 12.0% for PB and NP, respectively, 
for a [CD]tot of 13%; and [CD]free = 8% for SAL at [CD]tot = 9% (these high values for 
uncomplexed CD are due to the relatively low drug:CD binding constants, cf Table 5, 
and the very high CD/drug ratio). Therefore, the amount of CD free to interact with the 
polymer is necessarily higher than the value of 9% (in the case of PB and NP) and 7% 
(for SAL), which induce a similar micellar size reduction in free micelles (Table 4). 
The larger amount of effective cyclodextrin (in the presence of the drugs) compared to 
the free micelles (empty aggregates) needed to induce the same extent of rupture, 
indicates that the loaded micelles are overall more stable against rupture. These results 
demonstrate that the presence of all the drugs protects the micelles against rupture by 
DIMEB (mechanism 1) and cannot be attributed exclusively to the binding of the drug 
to cyclodextrins (mechanism (2)). While the involvement of drug:polymer interactions 
(mechanism (1)) in protecting the micelles against DIMEB had already been established 
for PB at 25ºC,1 it was not shown for NP and SAL at that lower temperature. Instead, 
here at 37°C we are able to show the important role of this mechanism in the protective 
effect of all the model drugs studied. Therefore, in the next section we measure the 
partitioning of the drugs within F127 micelles. 
 
Binding of drugs to F127 micelles  
The binding constant of the drugs to F127 micelles was measured at two drug 
concentrations (10-3 and 2%). The addition of F127 produces different changes in the 
drugs emission spectra, which are dependent on the drug and its concentration. In the 
case of NP and SAL, no change is observed al low drug concentration, while a 
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hyperchromic effect without spectral shift is observed at high drug concentration. This 
behaviour is the same as observed with the addition of DIMEB (previous section) and 
shows that no partitioning occurs at low NP or SAL concentration, and is not easily 
detected even at high concentration of SAL. Instead, in the case of LD, an increase in 
the emission intensity is observed at both drug concentrations studied (10-3 and 0.3%), 
confirming that partitioning takes place in both dilute and concentrated conditions. In 
addition, at 0.3% LD, a clear red shift in the emission band centered at 290 nm is 
observed (SI 5A), as observed when the polarity of the surroundings decreases,1 thus 
showing the transfer of LD from water to a less polar environment inside the 
aggregates. In the case of PB, an increase in the emission intensity is obtained - thus 
reflecting an interaction with F127 micelles – but no spectral shift (SI 5B). Considering 
the dependence of the position of the emission maximum on solvent polarity,1 this 
observation suggests that PB does not experience a large change in polarity when 
interacting with F127 micelles. These findings thus support a localization of LD deep 
inside the aggregates (in a non-polar region) and a localization of PB on the surface of 
the micelles, in close contact with the bulk water, which would thus explain the very 
limited structural changes to the micelles when loaded with PB (Figure 1A, Table 3). 
These considerations on drug localization are further discussed with results from 2D 
NMR (next section). 
Fitting the experimental data to Eq. 2 (Table 6, Figure 4) shows that increasing drug 
concentration produces an important increase in partitioning within the micelles. The 
dependence of partitioning on solubilizate concentration has been reported previously,31, 
32 but not widely studied and therefore is not well understood. Comparing the binding 
constants of these drugs to F127 at 37ºC with those previously obtained at 25ºC (shown 
in Table 6) also shows a strong increase with temperature. From a practical point of 
view, this is a very interesting result because the increase in partition increases the 
stability of the drug-micelle complex against dilution.32 In addition, a higher partition 
implies that a larger amount of drug molecules are present within the micellar phase 
than at lower temperature, hence their contribution to the stabilisation of the micelles 
should be higher, in good agreement with the important role of mechanism (1) at this 
temperature, pointed out for all the drugs, and not observed, but probably also 
important, at 25ºC. The increase in partition with temperature has been reported 
previously for other drugs33 and dyes.18 However, the increase of PB partition, in 
particular, is quite striking (more than 100 times higher than at 25ºC).  
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Overall, the trend in micellar partitioning, at both drug concentrations, is: PB > LD > 
NP > SAL. This result differs from that observed at 25°C where LD presented the 
highest partitioning.1 In octanol/water mixtures, the log P (= [solute]octanol/[solute]neutral, 
H2O) is defined to quantify the partition of neutral compounds. In ionisable molecules, 
partitioning depends on pH, hence a new parameter is defined to take into account the 
ionization process: log D = log [solute]octanol/([solute]neutral,H2O+[solute]ionized,H2O). The 
partitioning values at the measured natural pH of F127/drug solutions was estimated 
from a range of values provided at different pH,34 resulting in the following trend: SAL 
(-1.36) < NP (0.32) < PB (1.0) < LD (2.3). Clearly, salicylate has no tendency to 
partition in apolar octanol; this explains the difficulty in obtaining a measure of the 
binding to F127 (at low concentration) and the very low partition determined (at high 
concentration) (Table 6). The trend in Log D is in very good agreement with our 
results, except for PB that was found to partition much better than molecular LD.  
Partition in the micelles, however, does not seem to correlate with the protective effect 
of the drugs on the micelles; this is clearly demonstrated by PB behaviour, which 
presents the highest partitioning, but produces small changes in the size of the micelle, 
and is less effective than LD or NP in preventing the rupture of the micelles by DIMEB.  
The main difference of PB, compared to the other drugs, seems to be its surface 
localisation in the micelles (suggested by fluorescence spectroscopy). The specific 
localisation of a drug within a micelle is determined by the hydrophilic-hydrophobic 
balance of the drug and its specific structure, and this solubilisation locus, in turn, 
impacts drug loading.35 Therefore, a different localisation of PB – in a region matching 
its polarity - may explain its peculiar properties (i.e. high partitioning, striking increase 
in partitioning with temperature, low impact on micellar structure) and a lower 
protective effect against micellar disruption. 
Therefore, the localisation of the various drugs – more than the value of their 
partitioning - may be an important factor to consider. 
In order to examine this important parameter, we next use NOESY NMR to probe drug 
localization within the polymeric aggregates.  
 
Localisation of the drugs within the aggregates  
For all four drugs studied, 1H high-resolution spectra were obtained in pure D2O 
solution as well as in the presence of F127. No chemical shift or other spectral changes 
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of the drugs were observed by adding the polymer, confirming that no conformational 
changes are induced by the polymer.  
Useful information for the assessment of drug- polymer interactions can be obtained by 
2D NMR 1H-1H correlation spectroscopy based on the nuclear Overhauser enhancement 
(NOE). The fundamental theory and main applications to this type of systems have been 
reported in reference16 and are not repeated here. In the remaining of this section, F127 
spectral features are mentioned as a singlet at 1.13 ppm, assigned to the PPO methyl 
group, and a multiplet in the 3.68-3.42 ppm range, assigned to the PEO blocks. The 
proton spectra of the drugs are reported in Supporting information (SI 6-9). 
The NOESY spectrum of PB in Pluronic F127/D2O solution (SI 10) shows a strong 
overlap of the CH2 protons with PPO methyl group, thus severely limiting the 
possibility of using PPO methyl group as a probe for interaction. Nevertheless, the PEO 
signal (although affected by T1 noise) gives detectable cross peaks with PB, revealing 
an interaction between the polymer PEO protons with the three methyl groups of PB. 
This suggests a very superficial localisation of PB (or at least its apolar alkyl tail) within 
the micelles (Scheme 2), in very good agreement with previous fluorescence results1 
and the very limited changes in micellar structure upon drug partitioning (Figure 1A). 
1H-1H NOESY measurements of NP and F127 (SI 11) mixture reveal NOE cross peaks 
between the aromatic part of the molecule and the CH3 of PPO, indicating a close 
spatial relationship of the drug with the PPO blocks of the polymer. Unfortunately, the 
PEO signal is too strong and affected by T1 noise, thus it is not possible to assess 
whether it gives NOE with other protons. Despite this technical limitation, this result is 
in any case consistent with the aromatic part of NP interacting with the micellar core. 
Based on naproxen structure, having a hydrophobic naphthalene ring but a negative 
charge, a localisation at the core/shell interface is expected (Scheme 2). 
For salicylate, both 2D NOESY and ROESY experiments show an absence of cross 
peaks between the polymer and the drug molecule (SI 12). Similarly, no changes in the 
1H-NMR spectrum are detectable. These results show that SAL does not interact either 
with the micellar core or corona. Our partitioning data (Table 6) show a very limited 
partitioning of SAL within the micelles, reflecting a very low affinity for the polymer, 
despite the presence of an aromatic ring. A very low number of molecules partitioning 
could explain the impossibility of detecting cross-peaks with NMR. Indeed, at acidic pH 
(pH 1), where SAL becomes uncharged, strong NOE are detected, showing a 
localisation similar to NP (SI 13), and demonstrating the strong effect of charge on 
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partitioning. Recent studies by fluorescence (using C153 as a corona hydration probe)36 
suggest that both salicylic and salicylate ion reside in the corona region of Pluronic P85. 
Our combined results indicate that SAL in its ionized form is not inside the micelle, in 
spite of its interaction with the micelle (pointed out by changes in fluorescence and 
micellar structure by SANS), thus it is more likely to be adsorbed onto the micellar 
surface. 
Finally, with lidocaine, a severe overlap of drug and polymer signals hamper the 
interpretation of NOE data, as the signal from the CH3 protons of LD overlap with the 
methyl groups of PPO (SI 14). However, it is possible to establish that the aromatic 
protons of lidocaine do not show cross peaks with the PEO signals, thus reflecting a 
very limited interaction with the corona and supporting a deeper localisation of LD 
within the micelles, as also suggested by fluorescence (less polar microenvironment) 
and shown by SANS data (swelling of the core region). 
Overall, NMR data confirm that all drugs partition into different locations within the 
aggregates (Scheme 2), with LD partitioning close to the core, NP at the core/corona 
interface and PB near the surface. The solubilisation locus of SAL could not be 
determined, likely due to its very limited partitioning, but all results taken together 
suggest a more superficial localization than NP. With this knowledge, and to further 
examine the specific role of the localisation of these very different drugs on the stability 
of the micelles, we next measure their impact on F127 critical micellar concentration. 
 
Critical micelle concentration  
The cmc value of F127, alone and in the presence of each of the four drugs (SI 2), was 
determined in water using the method described in the experimental section (SI 1). 
The cmc value of F127 at 25ºC is 1.4± 0.13% (Table 1). This value is lower but in good 
agreement with the one obtained by Desai et al.37 by surface tension (2.0%) and ethyl 
orange spectral shift (2.5%), but higher than the value of 0.26% (0.20 mmol/dm3) 
obtained by Sharma et al. by SANS9 or 0.12% (w/v) obtained by surface tension 
measurements38 or by isothermal titration microcalorimetry (0.197 mM or 0.25% at 
28ºC).39 
The same spectral changes in the presence of the drugs were observed, namely, a blue 
shift of the absorption maximum. The presence of the drugs without F127 does not 
produce any change in the MO spectrum. Therefore, the changes observed correspond 
to the interaction of MO with F127. 
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The presence of LD produces a decrease in the cmc at 25ºC, in good agreement with the 
increase in micellar size observed by SANS. The addition of PB also leads to a decrease 
in the cmc to 0.9±0.3% (at 25ºC), showing that the presence of PB does affect the 
micellization ability of the polymer, despite SANS showing very little change in the 
size of the aggregates.1 Therefore, a stabilization of the micelles (lowering of the cmc) 
could explain the protective effect of both PB and LD against DIMEB at that 
temperature.1 In fact, our previous study at 25ºC had shown that the protective effect of 
PB could not be attributed to mechanism (2) alone.1 In contrast, the presence of both NP 
and SAL at 25ºC slightly increases the cmc of F127 (Table 1), in good agreement with 
the binding of charged species to the polymer chains inducing an increase in solubility, 
as described elsewhere for anions.40 
The increase in temperature produces a marked decrease in the cmc value of free 
micelles, as previously observed.39, 41 The same effect is observed in drug-loaded 
micelles. Solubilisation of LD inside the micellar core decreases the cmc at 37ºC, while 
it is increased with the other drugs: only slightly for PB and quite substantially for both 
NP and SAL. Interestingly, the cmc measurements at 25°C and 37°C confirm the 
contrasting effect PB has on the micellar structure at these two temperatures, shown by 
SANS and confirmed by diffusion NMR (Figure 1A and reference).1 
The free energy of the monomers inside the loaded aggregates is given by G0 = RT ln 
cmc, showing clearly that at higher temperatures the free micelles are more stable 
against disruption by DIMEB. The presence of LD further stabilizes the micelles against 
disruption, while at 37°C the other drugs (PB, NP, SAL) do not stabilize energetically 
the aggregates (as inferred from the higher cmc values) and the presence of these drugs 
is therefore unlikely to act as a preventive mechanism against micelle disruption. 
Moreover, the cmc of the NP-loaded micelles is higher than the free and PB-loaded 
micelles; its partition is also lower than PB (Table 6), but overall its protective effect is 
stronger (Figure 2A, Table 4).  
Since neither the cmc nor the extent of partitioning seem to directly correlate 
with the protective effect of the drugs against DIMEB, maybe the amount of drug 
molecules present inside the aggregates – which take into account both partitioning and 
micellar size – could explain the effects observed. For this purpose, we next used static 
light scattering (SLS) to determine the molecular weight of the micelles in the absence 
and presence of the drugs.  
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Number of drug molecules per micelle and Nagg (DLS and SLS) 
To gain further insight on the micellization of F127 in the presence of drugs and 
compare to the SANS data, the dimensions and molar mass of the micelles were 
obtained by DLS and SLS in D2O at 37ºC (Table 2). In agreement with SANS, micellar 
size is reduced slightly with drug loading (Table 3). With LD, the change is minor, but 
SANS had shown that the core was swollen by penetration of the drug (a difference in 
shell thickness – outside the detection limit of SANS – could explain the similar 
hydrodynamic size measured by DLS). The diffusion coefficients of NP and SAL-
loaded micelles as a function of concentration lie well above those of the free micelles, 
and PB and LD-loaded micelles (SI 15). The diffusion coefficients at infinite dilution 
are: 25.9 (F127), 26.4 (LD), 29.2 (PB), 31.2 (SAL) and 33.3 m2s-1 (NP), indicating 
unambiguously that free micelles diffuse more slowly than drug-loaded ones. The 
molecular weight of the micelles, determined by SLS, is also affected by the presence of 
the drugs (Table 2), as reported with P103 in the presence of flurbiprofen.42 Combining 
the values of the cmc (Table 1), MW of the loaded micelles (Table 2) and drug:F127 
binding constants (Table 6), and neglecting changes in partition with drug 
concentration, the number of drug molecules inside the micelles can be estimated 
(Table 2, SI 3). These results show that the number of drug molecules within the 
aggregates do not hold the key for the protective effect, for instance with a lower 
amount of NP being more efficient than a higher amount of PB or SAL molecules.  
 
Time-resolved SANS 
SANS measurements combined with a stopped-flow set-up add further insight into the 
role of drugs in hindering cyclodextrins-triggered disruption of micelles (Figure 5). 
These measurements were performed at 25ºC and a slightly lower concentration of F127 
(4%). When adding 5% DIMEB to Pluronic micelles loaded with 1% PB or NP, the 
break-up of the micelles is gradual: while there is a very fast drop in intensity after 100 
ms (second curve), which reflects an extensive break-up of the micelles, the next steps 
(to the final equilibrium structure) take 100s of seconds. This is in stark contrast to the 
free micelles, where the break-up was shown to be instantaneous (ca ~ 100 ms, the 
detection limit of the technique), namely: from the first frame at 100 ms, all curves 
superimposed perfectly.2 This result shows that the presence of drugs not only affects 
the equilibrium structure (more DIMEB is needed to achieve the same extent of rupture) 
but also seem to affect the kinetic pathways of the process.  
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As discussed above, the protective effect is not directly related to partitioning, neither to 
the number of drug molecules inside the aggregates. The slower kinetics point to 
processes taking place within the micelles, which could indeed be mediated by the 
precise localisation of the drugs within the aggregates. How can the locus of 
solubilisation determine the protective effect of these drugs against DIMEB? Previous 
results have shown that the methyl groups in position 3 of DIMEB interact with the 
methyl PPO groups of the micellar core, and that this interaction may be responsible for 
the break-up of F127 micelles.16 NP is located at the core/corona interface, so its 
presence could directly prevent the contact of DIMEB with the PPO core. PB is located 
far from the PPO methyl groups and nearer to the PEO corona, which is unlikely to be 
directly involved in the rupture by DIMEB, but PB could act by hindering the diffusion 
of CD to the micellar core from the micelle surface. Binding of the drugs to DIMEB 
within the aggregates may also be key to the protective effect. 
The formation/dissociation of drug/cyclodextrin inclusion complex have a lifetime in 
the range of milliseconds,30 while the exit of common arenes molecules from micelles 
takes around 10 ms.43 Overall, the timings revealed by TR-SANS demonstrate that it is 
not the snatching of the drugs from aqueous DIMEB nor inclusion complex formation 
in the aqueous pool which produce a delay time in breaking the micelles. Instead, the 
origin of drug protection seems to lie with events happening inside the aggregates, 
possibly involving the co-aggregation of these complexes within the aggregates, as has 
been observed elsewhere.44-46 
 
 
Conclusion 
In this work, we have studied the effect of four drugs of varying structures in reducing 
the extent of Pluronic F127 demicellisation, which is triggered by dimethylated β-
cyclodextrin (DIMEB). Using a wide combination of techniques, we have examined 
two possible mechanisms of protection: (1) a stabilization of the micelles by the drugs, 
controlled by drug-polymer interactions; (2) the role of drug:cyclodextrin inclusion 
complex formation (which leads to a lower effective amount of cyclodextrin molecules 
available to rupture the micelles). The large variation in drug structure and properties 
enables us to examine, one after the other, various factors that underlie these two 
mechanisms and could be responsible for micelle protection.  
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Our results show that the presence of these drugs in the aggregates impacts the size and 
structure of the loaded micelles in different ways (SANS data): while PB has a very 
small impact on micellar structure, SAL and NP reduce micellar size through intra-
micellar electrostatic repulsions, and LD swells the micellar core. We were able to 
relate these outcomes to drug structure and their solubilisation locus within the 
aggregates, for the first time measured by 2D NOESY NMR: PB has a very superficial 
localisation at the micellar surface, while NP is located at the core/corona interface; 
SAL localisation could not be detected (due to very low partitioning), but adopts a 
similar locus than NP at acidic pH; LD is localised in a non-polar environment, which 
concurs with its partitioning within the hydrophobic core. 
High temperature (37ºC) promotes the partitioning of all the drugs, while decreasing 
their binding to DIMEB. This shift in the balance of forces (compared to 25°C)1 enables 
us to establish that, at this temperature, the mechanism of protection is not due to a 
competitive complexation of the drugs with DIMEB (mechanism (2)); instead, it is the 
presence of the drugs within the aggregates which itself is responsible for the protective 
effect. However, cmc measurements show that the drugs do not increase the free energy 
of the monomers inside the aggregates (apart from LD) hence their impact on 
aggregation is not a protective factor in itself. 
Time-resolved SANS in the presence of drug-loaded aggregates reveal that the presence 
of drugs considerably slows down the process of rupture (to 100s of seconds), compared 
to the free micelles (< 100 ms).2 
Overall, our results show that neither partitioning, drug:CD binding, or the decrease in 
cmc hold the key to the protective effect of the drugs and their differences. It is 
suggested instead that processes taking place within the aggregates, thus modulated by 
the localisation of the drugs, impact micellar rupture. In particular, the co-aggregation 
of drug:CD inclusion complexes, or hindrance due to physical contact between DIMEB 
and the methyl groups of PPO, as previously suggested,16 may be responsible for this 
protective effect.  
On the whole, this work provides new insights into cyclodextrin-induced 
demicellisation, the importance of drug solubilisation locus within polymeric micelles, 
and inclusion complex formation between drugs and cyclodextrins, which are highly 
relevant to the controlled delivery of active compounds from polymeric micelles or 
cyclodextrins, but also offer a fundamental understanding into competitive molecular 
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processes that control interactions and thus equilibrium structures in multi-component 
systems. 
 
Supporting Information 
UV-Vis absorbance spectra of Methyl Orange (MO); calculations of the amount of free 
DIMEB and number of drugs inside F127 micelles; fluorescence emission spectra of 
drug-loaded micelles; NMR spectra; determination of the cmc from MO absorbance 
spectra; diffusion coefficient of the micelles obtained from DLS. This material is 
available free of charge at http://pubs.acs.org. 
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Table 1. Critical micellar concentration (cmc) of F127 micelles, free and loaded with 
1% drug (0.3 wt% for lidocaine), at 25°C and 37°C.  
 
 System cmc / wt% (298 K) cmc / wt% (310K) 
F127 1.4 ± 0.13 0.42 ± 0.013 
LD:F127 0.38 ± 0.12 0.174 ± 0.009 
PB:F127 0.9 ± 0.3 0.65 ± 0.09 
NP:F127 5 ± 2 1.7 ± 0.5 
SAL:F127 5 ± 1 0.8 ± 0.1 
 
 
 
 
Table 2.  Molecular mass, number of drug molecules inside the aggregates and 
aggregation number of F127 micelles in D2O at 37°C, in the presence of 1% drug 
(0.67% LD) determined by SLS and SANS.  
 
SYSTEM MW/kDa Ndrug Nagg 
Nagg 
/SANS 
F127 419 - 33  39 
Lidocaine 322 74 ± 23 24 56 
Pentobarbital 323 293 ± 24 20 37 
Naproxen 234 168 ± 22 15 26 
Salicylate 370 240 ± 30 26 30 
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Table 3. Structural parameters obtained from DLS (RH) and SANS for the free 
and drug-loaded F127 micelles (5%) in D2O at 37°C. SANS data were fitted to 
a core-shell form factor interacting through a hard-sphere structure factor; a 
Gaussian coil (Rg = 7 Å) was used to describe the contribution in the high-q 
region (cf. Experimental section).  
 
 
RH /nm 
DLS b 
Core 
Radius 
/Å 
Shell 
Thickness 
/Å 
Shell sld 
/Å-2 
Solvent 
penetration 
in shell /% 
Nagg 
Total 
radius 
/nm 
No drug  10.9b (3.1) 45 64 5.8910-6 92 40 10.9 
LD 0.67% 10.9 (1.8) 51 66 5.9110-6 92 56 11.7 
PB 1% 10.5 (2.0) 43 70 5.9410-6 92 37 11.3 
PB 2% - 43 68 5.9610-6 93 35 11.1 
NP 1% 10.1 (2.4) 39 63 5.9710-6 93 26 10.2 
NP 2% - 38 58 6.0710-6 95 23 9.6 
SAL 1% 10.3 (1.6) 41 64 5.9410-6 92 30 10.5 
SAL 2% - 39 62 5.9510-6 93 27 10.1 
a Obtained from cumulant analysis (standard deviation between brackets) 
b Measured at 4% 
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Table 4. Structural parameters obtained from SANS for the free and drug-
loaded F127 micelles (5%) with added DIMEB in D2O at 37°C (1% of all 
drugs, 0.65% for LD). The scattering data were fitted to a core-shell model 
interacting through a hard-sphere (HS) structure factor (for the micelles), to 
which a contribution of spheres of fixed radius (10 Å) was added to model the 
cyclodextrins. 
 
F127 micelles with: 
Core 
Radius 
/Å 
Shell 
Thickness 
/Å 
Shell sld 
/Å2 
HS 
volume 
fraction 
Polydispersity 
core/shell 
no drug, 5%DIMEB 42 55 6.1310-6 0.14 0.2/0.2 
no drug, 7%DIMEB 37 50 6.0810-6 0.10 0.2/0.2 
no drug, 9%DIMEB 28 32 5.8910-6 0.03 0.2/0.2 
LD, 11% DIMEB 35 49 6.0310-6 0.11 0.2/0 
LD, 13% DIMEB 29 44 5.9610-6 0.07 0.2/0 
PB, 9% DIMEB 41 60 6.2010-6 0.15 0.2/0.2 
PB, 11% DIMEB 36 59 6.2510-6 0.12 0.3/0 
PB, 13% DIMEB 26 54 6.1510-6 0.09 0.25/0 
NP, 9% DIMEB 41 60 6.1910-6 0.15 0.2/0.2 
NP, 11% DIMEB 33 53 6.1310-6 0.10 0.2/0.2 
NP, 13% DIMEB 28 54 6.1410-6 0.10 0.2/0 
SAL, 9% DIMEB 35 57 6.1710-6 0.11 0.25/0 
SAL, 13% DIMEB 24 35 6.1510-6 - - 
 
 
 
Table 5. Drug:CD binding constant K/X-1(g/g of complex) at 37ºC determined using 
Eq. 3. The concentration of drug is Cdrug = 10-3 wt%. The wavelength of the maximum 
of fluorescence used is shown between brackets where the spectrum presented more 
than one maximum. The values of K shown between brackets correspond to the values 
measured at 25ºC (reproduced from 1).  
 
 
DRUG K /X-1(g/g) 
Lidocaine 3±0.1 (F290)/ (3.80±0.1) 
Pentobarbital 20±2 (F355) /(48.92±1.9) 
Salicylate 423±3/(440.9±30.1) 
Naproxen 468±133/(625±25) 
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Table 6. Binding constant K/ X-1(g/g) of the drugs to F127 Pluronic micelles in 
a 5 wt% micellar solution at 37ºC determined using Eq. 2. Two drugs 
concentrations are studied: (a) diluted: with Cdrug = 10-3 wt% and (b) 
concentrated: Cdrug = 2 wt% (except for lidocaine where Cdrug = 0.3 wt%). The 
cmc values used are given in Table 1. The values measured at 25ºC are shown 
between brackets (reproduced from 1).  
 
DRUG K /X-1(g/g) 
Diluted 
K /X-1(g/g) 
Concentrated 
lidocaine 9 ± 0.05 (F330)/(1.50±0.13) 140 ± 32(F295)/(34.5±0.9) 
pentobarbital 10 ± 2 (F340)/(8.83±0.99) 1167 ± 20 (F297)/(7.79±2.0) 
naproxen Not detected 45.6±0.5/(3.56±0.95) 
salicylate Not detected 18.3±0.34/(4.67±0.37) 
 
30 
 
Figure Captions 
 
Figure 1: Small-angle neutron scattering curves from 5% F127 micelles at 37°C with 
various amounts of the four drugs loaded: A. with 0.5, 1 and 2% pentobarbital (inset: 
same data in a lin-log plot to highlight changes in intensity) with varying drug content); 
B. with 1 and 2% naproxen or salicylate; C. as in B, but with curves staggered. D. with 
0.67% lidocaine. 
Figure 2: Small-angle neutron scattering curves from 5% F127 micelles with and 
without the four drugs studied and increasing amounts of DIMEB. Figures on the right-
hand-side are the same as on the left hand-side but staggered for better visibility; the 
left-hand side figures are included to better visualise the overlap of some of the curves. 
A. Comparison between pentobarbital and naproxen: 5% F127 with 5, 7 and 9% 
DIMEB and the same micelles with either 1% pentobarbital and 9, 11 and 13% DIMEB 
or 1% naproxen and 9 and 13% DIMEB. B. Comparison between naproxen and 
salicylate: 5% F127 loaded with 1% salicylate or naproxen; 5% F127 micelles with 7% 
DIMEB and the same micelles with either 1% salicylate or naproxen and 9 and 13% 
DIMEB. C. Comparison of pentobarbital and lidocaine: 5% F127 loaded with either 1% 
pentobarbital and 0.67% lidocaine and 11 and 13% DIMEB. D. As in A but staggered 
curves. E. As in B but staggered curves. F. As in C but staggered curves. 
Figure 3. Change of the fluorescence intensity (circles) and fits to Eq. 3 (solid line) for 
drugs (10-3% wt)  A. in the absence and B. presence of 5% F127, at increasing DIMEB 
concentrations. 
Figure 4: Change in fluorescence intensity (circles) and fitting to Eq. 2 (solid line): of 
A. 0.3% LD; B. 2% PB; C. 2% NP and D. 2% SAL in the presence of increasing 
amounts of F127. 
Figure 5: Small-angle neutron scattering data from 4 wt% F127 micelles with drug, 
either A. 1% PB or B. 1% NP, in the presence of 5% DIMEB at different time points 
after mixing: 0.1 s, 1.5 s, 111.1 s, 622.1 s, and 642.1 s at 25ºC. 
Scheme 1. Chemical structure of lidocaine, sodium pentobarbital, naproxen sodium salt, 
and sodium salicylate. 
Scheme 2: Solubilisation locus of the drugs in the polymeric micelles as inferred from a 
combination of SANS, UV spectroscopy and 2D NMR as described in the text.  
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5.  
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Scheme 1.  
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Scheme 2 
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